# Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

> **NCT01703468** · PHASE1 · COMPLETED · sponsor: **Roxane Laboratories** · enrollment: 59 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Oxcarbazepine

## Key facts

- **NCT ID:** NCT01703468
- **Lead sponsor:** Roxane Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703468, "Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01703468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*